Affymax, Inc., a biopharmaceutical company, engages in the development of peptide-based drug candidates to enhance the treatment of serious and life-threatening conditions. Its lead product candidate includes Hematide, a synthetic peptide-based erythropoiesis stimulating agent, which is designed to treat anemia associated with chronic kidney disease and cancer. The company is conducting phase II clinical trials of Hematide in dialysis patients, predialysis patients, cancer patients on chemotherapy and patients with PRCA. It is also developing a pipeline of peptide based drug candidates, including Adeptide, a peptide based, non-injectable erythropoiesis stimulating agent; the Innotide program that comprises a family of peptide based drug candidates for use in the area of tissue protection in preclinical models of stroke, myocardial infarct, and renal injury; and Angiotide, a synthetic peptide for treating cancer by blocking angiogenesis, or blood vessel formation in tumors. Affymax has strategic alliances with Takeda Pharmaceutical Company Limited to develop and commercialize Hematide; EntreMed, Inc. for preclinical research of Angiotide; and Nektar Therapeutics AL, Corporation. The company was founded in 2001 and is based in Palo Alto, California.